Seeking Alpha

Gilead Sciences (GILD +4.7%) is one of the best performers in the S&P 500 today after...

Gilead Sciences (GILD +4.7%) is one of the best performers in the S&P 500 today after JPMorgan analyst Geoff Meacham came out with some positive comments about the company's new HIV medication Stribild and hepatitis C drug program, and raised his price target to $75 from $70.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs